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Uncontrolled increases of matrix metalloproteinase-9
(MMP-9) activity have been causally linked to epithe-
lial barrier disruption and severe symptoms of in-
flammatory diseases such as dry eye (DE). The data
presented here show that the anti-inflammatory, cy-
toprotective intracellular and extracellular chaperone
protein clusterin (CLU) interacts with MMP-9 both
inside and outside epithelial cells. CLU bound very
strongly to active MMP-9, with an affinity constant KD
of 2.63 nmol/L. Unexpectedly, CLU had a much higher
affinity for pro-MMP-9 than for active MMP-9 or pro-
MMP-2, requiring the N-terminal propeptide domain
of pro-MMP-9. The significance of the interaction be-
tween CLU and MMP-9 was demonstrated by the ob-
servation that CLU prevents stress-induced MMP-9 ag-
gregation and inhibits MMP-9 enzymatic activity.
Furthermore, CLU inhibited MMP-9-mediated disinte-
gration of the tight junction structure formed be-
tween human epithelial cells. Additionally, CLU inhib-
ited enzymatic activities of MMP-2, MMP-3, and
MMP-7. Treatment with proinflammatory cytokines,
which are known to increase MMP-9 transcription
under inflammatory conditions, reduced the expres-
sion of CLU in human epithelial cells. Similarly, in a
mouse model of human DE, inflammatory stress de-
pleted CLU in the ocular surface epithelium but al-
lowed MMP-9 to prevail therein. The present results
thus provide novel insights into previously unrecog-
nized mechanisms by which CLU maintains fluid-ep-
ithelial interface homeostasis, thereby preventing the
onset of inflammatory conditions, especially where
2028MMP-9 is actively involved. (Am J Pathol 2012, 180:
2028–2039; DOI: 10.1016/j.ajpath.2012.01.025)
The epithelial cell lining of structures that face the exter-
nal environment, such as the airway and ocular surface,
is frequently subject to chronic or acute inflammation. An
inflammatory morbidity of the ocular surface, dry eye
disease (DE), affects approximately 4.9 million Ameri-
cans over the age of 50 years.1 The burden to the patient
is substantial, adversely affecting visual function and
quality of life, with few therapeutic options.
The matrix metalloproteinases (MMPs) are a family of
extracellular zinc-dependent endopeptidases whose ac-
tivity is tightly regulated at multiple stages, including tran-
scription, secretion, activation, activity, and clearance.2,3
MMPs play diverse roles in maintenance and repair of the
ocular epithelium.4 MMP-9 is secreted as inactive pro-
MMP-9, and the N-terminal propeptide of pro-MMP-9
blocks the catalytic domain by binding intramolecularly
through the cysteine-zinc bridge between these two do-
mains.5 MMP-9, which is induced by damage to the cor-
neal epithelium, coordinates multiple events in the pro-
cess of corneal epithelial regeneration; either too little or
too much MMP-9 leads to undesirable outcomes.6,7 Stud-
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that excessive MMP-9 activity is associated with abnor-
mal corneal wound-healing processes.6–8 Increased
MMP-9 activity has also been shown to play a causal role
in the destruction of the corneal epithelial barrier in DE
disease,9 and was strongly correlated with severe clinical
symptoms in patients with DE.10 Recently it has been
suggested that increased MMP-9 affects cell prolifera-
tion,11 which further emphasizes the damaging role of
MMP-9 in inflammatory disease.
CLU (alias apolipoprotein J or Apo-J) has three iso-
forms with distinct subcellular locations. The secreted
form (sCLU) is a heterodimeric glycoprotein (80 kDa)
composed of disulfide-linked  (34 to 36 kDa) and  (36
to 39 kDa) subunits derived inside cells from a pres-
ecreted, glycosylated peptide (psCLU) (60 kDa); sCLU
works as an extracellular molecular chaperone for numer-
ous protein ligands.12,13 sCLU and psCLU proteins have
been suggested to play cytoprotective, anti-inflammatory
roles in various organs (see reviews by Trougakos et al13
and by Falgarone and Chiocchia14). Nuclear CLU
(nCLU), a product of an alternative splicing of pre-mRNA,
is correlated with the apoptotic response of cells to cer-
tain stimuli, including ionizing irradiation.15
sCLU facilitates the clearance of denatured proteins,
protein aggregates, proteinases, and dead cell de-
bris,16–18 interacts with the cell surface receptor, low-
density lipoprotein receptor-related protein 2 (LRP-2)
(LRP-2/megalin/gp330),19 protects the cells from oxida-
tive stress,20 and inhibits immune complement-mediated
cytolytic activity.21–23 psCLU protects from cell death by
blocking the intracellular activity of Bax,24 and sCLU pro-
tects some cell lines from TNF--mediated cell death.25
psCLU also stabilizes I-B and inhibits nuclear NF-B
translocation,26–28 which is one of the key events in-
volved in inflammation. Overexpression of CLU was
shown to inhibit MMP-9 expression mediated by the
NF-B pathway.28 Results from several genetic studies
using CLU-deficient mice have supported the protective
role of CLU during inflammation in various organs.29–33
Even though MMP-9 is a critical factor in ocular surface
inflammation, molecular studies are required for better
understanding of how its activity is regulated. With the
present study, we show that CLU proteins interact with
MMP-9 in unique ways, interfering with its biochemical
activity and function. These data provide new insight into
important roles of CLU in ocular surface homeostasis and
in the prevention and treatment of inflammatory disease.
Materials and Methods
Cell Culture
Cells of the human embryonic kidney cell line HEK293 and
the human breast cancer cell line MCF-7 were grown in
Dulbecco’s modified Eagle’s medium containing 10% fetal
bovine serum, 100 U/mL penicillin, and 100 g/mL strepto-
mycin in a cell culture incubator at 37°C and 5% CO2.
Immortalized human corneal-limbal epithelial (HCLE) cells,
kindly provided by Ilene Gipson (Harvard University), weregrown in Gibco keratinocyte serum-free medium (Invitro-
gen, Carlsbad, CA), as described previously.34
MMP-9 cDNA Construction
The entire MMP-9 cDNA (coding amino acids 1 to 703)
was reverse-transcribed and amplified from mouse mus-
cle tissue. Primers MMP9.1 (5=-GGCGCCGAATTC-
ATGAGTCCCTGGCAGCCCCTG-3=) and MMP9.2109
(5=-GGGCCCGTCGACTCAAGGGCACTGCAGGAGGTCGT-
AGGTCA-3=) were used, incorporating EcoRI and SalI
sites, respectively. This RT-PCR product was inserted
into the yeast expression vector pGBKT7 and labeled
pGB-M9. Using the pGB-M9 plasmid as a template, an
N-terminus MMP-9 truncated PCR product missing the
signal and propeptide domain (amino acids 109 to 703)
was generated using MMP-9.325 (5=-GGCGCCGAATTC-
CAAACCTTCAAAGGCCTCAAGTGGG-3=) and MMP9.2109
primers and labeled pGB-M9PP. The glutathione S-trans-
ferase (GST)-tagged MMP-9 constructs were generated by
ligation of the pGB-M9 and pGB-M9PP EcoRI/SalI inserts
into the pGEX 4T vector (Amersham; GE Healthcare, Pis-
cataway, NJ).
Library Construction and Screening
Whole mouse cornea was excised and total RNA was
isolated using TRIzol reagent (Invitrogen). The cDNA li-
brary was synthesized using 2 g total RNA and random
primers according to the protocol for the Matchmaker
yeast two-hybrid system (Clontech, Mountain View, CA).
This system uses an in vivo library construction method;
the cDNA library and the linearized yeast expression
vector pADT7-Rec were therefore simultaneously trans-
fected into the AH109 pGB-M9PP stable yeast cells.
Positive colonies were selected on quadruple knock-out
plates (ie, yeast minimal agar plates lacking tryptophan,
leucine, histidine, and adenine). The histidine and ade-
nine reporter genes were used to test for interactions. An
additional screen involved the addition of X--galactosi-
dase to the quadruple knock-out medium, whereby a
positive interaction allowed for blue/white screening.
For yeast plasmid isolation, positive colonies were in-
oculated into an overnight culture of yeast agar peptone
dextrose (YAPD) medium, and plasmid isolation was per-
formed on saturation using a yeast lysis method as fol-
lows. Briefly, pelleted yeast cells were mixed in a vortex
mixer in equal volume yeast lysis buffer (2% Triton X-100,
1% SDS, 0.1 mol/L NaCl, 10 mmol/L Tris-HCl (pH 8.0), 1
mmol/L EDTA) and phenol-chloroform-isoamyl alcohol
(25:24:1) with acid-washed glass beads. The clarified
supernatant was ethanol-precipitated in the presence of
NaOAc. The resulting DNA complex was transformed into
XL1-blue bacterial cells, and colonies were selected on
ampicillin plates (to select for the pADT7-library clone). The
resulting bacterial colonies were lysed via the standard
alkaline lysis protocol and the plasmids were sequenced.
The DNA sequences were translated based on the reading
frame given for the pADT7-Rec vector, and both the protein
sequence and the DNA sequence were subjected to Gen-
Bank BLAST searches (http://www.ncbi.nlm.nih.gov/blast).
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quences using a translation software tool (http://www.
ncbi.nlm.nih.gov/projects/gorf). Dual searches were per-
formed to confirm that the protein sequences translated
matched their DNA sequences; mismatching clones were
discarded.
GST Pull-Down Assay
The GST-tagged MMP-9 constructs were generated by
ligation of the pGB-MMP-9 EcoRI/SalI inserts into the
pGEX 4T vector (Amersham; GE Healthcare). The
pGEX 4T MMP-9 constructs were transformed into the E.
coli strain BL21(DE3) (Novagen; EMD Chemicals,
Gibbstown, NJ) for expression. The bacterial pellet was
prepared from a 100-mL culture that was grown to mid-
log phase, induced with 0.4 mmol/L isopropyl -D-thio-
galactopyranoside for 3 hours, and then centrifuged. The
pellet was resuspended and lysed by sonication in ST
buffer (50 mmol/L Tris pH 7.4, 100 mmol/L NaCl, 1 g/mL
leupeptin, 1 g/mL aprotinin, 1 mmol/L phenylmethylsul-
fonyl fluoride, 1 mmol/L NaF), and GST-MMP-9 protein
was purified via incubation with glutathione-coated
beads (Amersham; GE Healthcare) overnight at 4°C. On
the next day, the beads were extensively washed in ST
buffer. To confirm production of GST-MMP-9 protein, pro-
teins bound to the beads were resolved on a denaturing
8% SDS-PAGE gel. The gel was subjected to Coomassie
Brilliant Blue staining or transferred to polyvinylidene di-
fluoride membrane and immunoblotted using a rabbit
polyclonal antibody to MMP-9 (Triple Points Biologics,
Forest Grove, OR). With a TNT quick coupled transcrip-
tion/translation system (Promega, Madison, WI), the
pADT7-CLU clone was used to generate a CLU-HA fu-
sion protein. Beads coated with GST-MMP-9 or GST were
incubated with equal amounts of CLU-HA overnight at
4°C in immunoprecipitation (IP) buffer (50 mmol/L Tris pH
7.4, 100 mmol/L NaCl, 0.1% Triton X-100, 1 g/mL leu-
peptin, 1 g/mL aprotinin, 1 mmol/L phenylmethylsulfonyl
fluoride, 1 mmol/L NaF) in the presence or absence of
1 mg/mL BL21 bacterial soluble extract (to decrease
nonspecific background). On the next day, the beads
were washed three times in IP buffer, before the pro-
teins were eluted from the beads into SDS-PAGE load-
ing buffer, which was subjected to Western blotting
using a mouse HA antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA).
Generation of Expression Vectors for MMP-9
and CLU
The pcDNA3.1() expression vector (Invitrogen) was used
to insert PCR fragment generated using pGB-M9 as a tem-
plate with the gene-specific primers containing EcoRI sites
(forward primers) or NotI sites (reverse primers): mouse
CLU with a C-terminal Myc tag (CLU-Myc), 5=-GATC-
GAATTCATGAAGATCTCCTGCTGT-3= and 5=-CGATGCG-
GCCGCTCACAGGTCCTCCTCTGAGATCAGCTTCTGCTC-
TTCCGCACGGCTTTTCCT-3=; mouse MMP-9 with a C-ter-
minal HA tag (MMP-9-HA), 5=-GATCGAATTCATGAGTC-CCTGGCAGCC-3= and 5=-CGATGCGGCCGCTCAAGCGTA-
ATCTGGAACATCGTATGGGTAAGGGCACTGCAGGGT-3=.
The DNA sequence of cloned DNA was confirmed by DNA
sequencing.
Surface Plasmon Resonance Analysis
The SensíQ Pioneer system (ICx Nomadics, Oklahoma
City, OK) was used for all surface plasmon resonance
measurements at a constant temperature of 25°C. The
running buffer for the SensíQ Pioneer system was 20
mmol/L HEPES pH 7.4, 150 mmol/L NaCl, 1 mmol/L
EDTA, and 0.01% Tween-20. An ICx COOH5 sensor chip,
which comprises a high-capacity charged polysaccha-
ride for amine coupling of target molecules, was used for
all experiments. For kinetic analysis of CLU binding
MMP-9, recombinant catalytic domain of MMP-9 was im-
mobilized to the COOH5 sensor by direct amine cou-
pling. Amine coupling of MMP-9 was performed accord-
ing to the manufacturer’s protocol, in which MMP-9 is
diluted in acetate buffer (pH 4.3). A solution of CLU-His
(R&D Systems, Minneapolis, MN) was prepared in run-
ning buffer, and a serial doubling dilution series was
prepared according to the SensiQ Pioneer protocol with a
top concentration of 100 nmol/L. Each concentration in
the series was injected for 3 minutes over three sensor
channels that contained either MMP-9 or a blank refer-
ence channel. Dissociation of each injection was moni-
tored for 6 minutes. Kinetic analysis of all response
curves was performed using Qdat analysis software (ICx
Nomadics and BioLogic Software, Campbell, Australia).
The binding data were zeroed and referenced by sub-
tracting the response of the reference channel and a
buffer blank injection. A simple 1:1 kinetic model was
fitted to the data, where the rate constants of association
(ka) and dissociation (kd) were globally constrained for
the assay.
Immunoprecipitation Assay
HEK293 cells were grown in subconfluent culture in a
six-well plate and were transfected with 2.5 g of
pcDNA3.1()/MMP-9-HA, pcDNA3.1()/MMP CLU-Myc,
or both, using Lipofectamine LTX according to the man-
ufacturer’s instruction (Invitrogen). At 1 day after trans-
fection, whole-cell extracts were prepared using radioim-
munoprecipitation assay buffer, incubated with anti-HA
antibody to immunoprecipitate MMP-9-HA and partners.
The complexes were resolved on a denaturing 8% SDS/
PAGE gel for immunoblotting to detect CLU-Myc proteins
with anti-Myc antibody.
Immunofluorescence Staining
HCLE cells (5000 cells/well, for 2 days) and MCF-7 cells
(25,000 cells/well for 4 days) were grown in a 16-well
chamber slide before immunocytochemical analysis. The
HCLE cells were washed once with PBS and then fixed in
ice-cold methanol for 10 minutes. Next, the cells were
washed three times with PBS, followed by blocking with
1% bovine serum albumin and 0.25% Triton-X 100 in PBS
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incubated at room temperature for 45 minutes with both
goat anti-CLU (1:50) (Santa Cruz Biotechnology) and
rabbit anti-MMP-9 (1:50) (Abcam, San Francisco, CA)
antibodies in the blocking solution. After the primary an-
tibody incubation, cells were washed three times with
PBS for 5 minutes each and then were incubated at room
temperature for 1 hour with both donkey Alexa Fluor 488
anti-goat IgG (1:2000) and goat Alexa Fluor 594 anti-
rabbit IgG (1:2000) secondary antibodies. Cells treated
with the secondary antibodies alone were used as a
negative control. Subsequently, the cells were washed
three times with PBS for 5 minutes each and rinsed once
with distilled water. The cells were then covered with a
drop of Vectastain containing DAPI (Vector Laboratories,
Burlingame, CA) and coverslipped. For ZO-1 degrada-
tion experiments, MCF-7 culture was exposed to 25 ng
of catalytic domain of MMP-9 in the presence or ab-
sence of 6 g of recombinant CLU in fetal bovine
serum-free Dulbecco’s modified Eagle’s medium for 4
hours in a CO2 incubator in duplicate for each set. The
cells were processed as above for fluorescent staining
with anti-ZO-1 (1:50) and Alexa Fluor 488 anti-goat IgG
antibodies (1:500).
The cells were imaged on an UltraVIEW ERS spinning
disk laser confocal microscope (PerkinElmer, Waltham,
MA) at magnification 400, with Z-stacking at 0.5-m
intervals. A total of 12 images per each set were obtained
randomly, in Z-stacking, and the general densities of
ZO-1 were quantified with PerkinElmer Volocity software
version 5.4. For Western blotting, 40 g of whole-cell
extract was loaded onto 8% denaturing SDS/PAGE
gel. Antibody for -actin (1:5000) was purchased from
Abcam.
MMP Inhibition Assay
Recombinant mouse CLU with C-terminal (His)6 tag
(sCLU), MMP-2, and MMP-7 were purchased from R&D
Systems (Minneapolis, MN); MMP-9 was purchased from
AnaSpec (Fremont, CA). The recombinant catalytic do-
main of human MMP-9 (residue 112 to 445) was pur-
chased from AnaSpec and from ProtEra (Sesto Fiorentino,
Italy). A gelatinase-specific synthetic inhibitor, SB-3CT, was
obtained from Biomol International (Plymouth Meeting,
PA). MMPs were mixed with CLU in TSCB buffer (50
mmol/L Tris-HCl pH, 7.5, 150 mmol/L NaCl, 5 mmol/L
CaCl2, 0.002% Brij-35) for 30 minutes before addition of
substrate, and were incubated for 3 hours at room tem-
perature in the presence or absence of 0.02 mmol/L
p-aminophenylmercuric acetate (APMA). The APMA was
added only when pro-MMPs were used. MMP activity
was measured using a 5-FAM/QXL520 fluorescence res-
onance energy transfer (FRET) peptide as a substrate
(excitation, 490 nm; emission, 520 nm) (AnaSpec), ac-
cording to the manufacturer’s protocol. Relative fluores-
cence units (RFU) were obtained by subtracting the val-
ues of APMA- or enzyme-omitted reactions from those of
test samples, and then considering the fluorescence unit
of PBS (vehicle) sample as 100%. Enzyme reactions were
performed in a black 96-well plate, containing combina-tions of pro-MMP-2 (10 ng), catalytic domain of MMP-3
(20 ng), pro-MMP-7 (5 ng), catalytic domain of MMP-9 (5
ng), and sCLU (2.5 g or 0.6 mol/L, or otherwise as
indicated) in 50-L reaction volume, where pro-MMPs
were activated by APMA-induced processing of the
pro-MMPs. As MMP substrates (0.4 mol/L), 520 MMP
FRET substrate I, QLX520-Pro-Leu-Gly-Leu-Trp-Ala-D-
Arg-Lys(5-FAM)-NH2, was used for MMP-2, MMP-3,
and MMP-9, and 520 MMP FRET substrate XIV, QXL520-
-Abu-Pro-Cha-Abu-Smc-His-Ala-Dab(5-FAM)-Ala-Lys-
NH2, was used for MMP-7 reactions; both were pur-
chased from AnaSpec. Fluorescence was monitored us-
ing a Victor3 V multilabel counter (PerkinElmer). For the
gelatin digestion, a 50-L mixture of gelatin (20 g) and
CLU (2 g) was incubated with or without active MMP-9
(70 ng) for 2 hours at 37°C. The reaction products were
run on a 12% denaturing SDS/PAGE gel for Coomassie
Brilliant Blue staining.
Gelatin Zymography
Zymography to analyze the relative amounts of MMPs
was performed according to the procedure described by
Gordon et al.35 Briefly, samples were loaded onto an 8%
PAGE gel containing 0.1% gelatin (Sigma-Aldrich, St.
Louis, MO). Gels were run for 45 minutes at 200 V. Gels
were then incubated in 2.5% Triton-X for 1 hour at room
temperature on a rocker. Gels were thoroughly washed
with distilled water and incubated overnight in renaturing
buffer (10 mmol/L CaCl2, 50 mmol/L Tris-HCl pH 7.5) at
37°C. The next morning, gels were briefly washed and
then stained (25 g Coomassie Brilliant Blue, 150 mL iso-
propanol, 50 mL acetic acid, 300 mL distilled deionized
water) for 1 hour at room temperature on a rocker. Gels
were then destained in distilled water until bands were
clearly visible. Gels were then scanned for densitometric
analysis using ImageJ software version 1.45 (NIH, Be-
thesda, MD).
MMP Enrichment Assay
To make various processed forms of MMPs, pro-MMPs
were incubated with 1 mmol/L APMA in TSCB buffer at
37°C for 4 hours.36 CLU-His (2.5 g) was incubated with
a mixture of 30 to 100 ng of unprocessed and processed
pro-MMP-2 and pro-MMP-9 in TSCB buffer for 1 hour at
4°C, followed by additional incubation for 1.5 hours with
anti-His tag antibody-conjugated agarose beads. The
beads were washed three times with the binding buffer
and then were dissolved in 1 SDS sample loading buf-
fer. Relative amounts of bound MMPs were assessed
from the gelatin zymography. To perform CLU binding
domain analysis, CLU-His coupled to beads was prein-
cubated with enough pro-MMP-9 to saturate all of the
CLU molecules on the beads (confirmed by detection of
a great quantity of unbound pro-MMP-9 after the prein-
cubation); the beads were then purified and divided into
two aliquots. These beads were incubated with and
without 1 mmol/L APMA at room temperature for 1 hour
in TSCB buffer on the rotator. The bead fraction was
spun down and the supernatant was separated. The
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SDS sample loading buffer. Equivalent volumes of su-
pernatant and bead fractions were subjected to gelatin
zymography.
MMP Aggregation Assay
The pro-MMP-2 and MMP-9 (5 ng/tube), individually or in
combination, were incubated in TSCB buffer containing
0.04% nonionic detergents (Brij-35, NP-40, or n-octyl glu-
copyranoside) in the presence of CLU-His (1.25 g/tube)
or PBS (vehicle control) at room temperature for 80 min-
utes, followed by microcentrifugation for 2 minutes at
21,000  g to separate the soluble and insoluble frac-
tions, which were resolved in zymography. Densities of
the bands were quantified using ImageJ analysis. Rela-
tive solubility was calculated by dividing the density of
soluble band with the combined densities of soluble and
insoluble bands in each set of reactions.
RT-PCR of CLU and MMP-9 Induction
HCLE cells were stratified for 7 days according to the
procedure described by Gipson et al37 and were sub-
jected to serum starvation for 6 hours before treatment
with IL-1, TGF-2, and TNF- (0 ng/mL each) and PMA
(1 mol/L) for 24 hours. cDNA synthesized from total RNA
from each treatment was subjected to RT-PCR using
primer sets of human MMP-9, CLU, and -actin cDNA.
Fold induction (versus untreated control) of gene expres-
sion were assessed by the Ct method using -actin
expression as a denominator. Primer sequences were as
follows: -actin, 5=-CATTGCCGACAGGATGCAGA-3= and
5=-CTGATCCACATCTGCTGGAA-3=; MMP-9, 5=-TTGA-
CAGCGACAAGAAGTGG-3= and 5=-TCACGTCGTCCTTA
TGCAAG-3=; and CLU, 5=-ACCAGTACTATCTGCGGG-
TCA-3= and 5=-CGTCACAGTGATGGGATCAG-3=.
Experimental DE Induction
The research protocol was approved by the University of
Southern California, Department of Animal Resources
and the Institutional Animal Care and Use Committee,
and it satisfied the standards in the ARVO Statement for
the Animals in Ophthalmic and Vision Research.
DE was experimentally induced in 8-week-old
C57BL/6J female mice for 6 days according to the meth-
ods described by Corrales et al.38 Briefly, scopolamine
hydrobromide (Sigma-Aldrich) at 0.5 mg/0.2 mL in PBS
was injected four times a day. An air draft was applied to
the perforated cages for 18 hours per day in a vivarium
with 40% humidity and with a temperature of approxi-
mately 80 2°F. To measure tear production, we applied
cotton threads to the ocular surface for 15 seconds and
measured the amount of tear fluid uptake in millimeters.9
For immunofluorescent staining, mice were euthanized
and eyes were surgically excised, embedded into opti-
mum cutting temperature compound, stored at 80°C,
and used for frozen sectioning (10 m thick). Rabbit
Anti-CLU (1:50) (Abcam, San Francisco, CA) and goat
anti-MMP-9 (1:100) (Santa Cruz Biotech, Santa Cruz, CA)were used as primary antibodies. Alexa Fluor 594 anti-
rabbit IgG (1:2000) and Alexa Fluor 488 anti-goat IgG
(1:2000) antibodies were used for immunofluorescent
staining, followed by image analysis using a Zeiss LSM
510 multiphoton laser scanning confocal microscope (0.3
m-interval Z-sectioning) and a 40 oil-immersion objec-
tive. Frozen sections treated with normal IgG or with the
secondary antibodies were used as a negative control.
Images from untreated and DE-induced samples were
captured and processed with identical photomultiplier
tube gain settings, allowing accurate comparison for ev-
ery pair. The eyes were washed with 5 L of PBS, 2.5 L
TRIzol (Invitrogen) was applied to the ocular surface, and
epithelial cells were scraped from the ocular surface.
From these cells we isolated total RNA and proteins ac-
cording to the manufacturer’s protocol, to perform quan-
titative RT-PCR and Western blotting. Protein extracts
from individual eyes from each group were pooled to
prepare protein extract in amounts sufficient for Western
blotting. The same membrane was used for CLU and
-actin probing after stripping the membrane of proteins
from the first blotting. Primers for mouse MMP-9 and
GAPDH were as reported by Luo et al.39 The primers for
mouse CLU were 5=-CCAGACGTGGATTTCTTAAGA-
GAA-3= and 5=-AGGATTGTTGGTTGAACAGTCC-3=. Rel-
ative expression of CLU and MMP-9 was calibrated by
the expression of GAPDH.39
Results
CLU Interacts with MMP-9 in Vitro and in Vivo
To search for new MMP-9-interacting proteins, yeast two-
hybrid screening was performed, for which we used
mouse MMP-9 cDNA encoding the active form of MMP-9
as bait, resulting in the selection of 24 potential prey
sequences including CLU cDNA (see Supplemental Ta-
ble S1 at http://ajp.amjpathol.org). The yeast CLU clone
that was isolated from the yeast assay contained CLU
cDNA beginning at position 212 from the ATG site and
thus lacked N-terminal 71 amino acids (CLU71). To
verify their interaction, we performed a GST pull-down
assay using MMP-9-GST and CLU 71-HA fusion pro-
teins, both expressed in a bacterial system (Figure 1A).
MMP-9-GST-coated beads pulled down CLU71-HA in
this assay, even in the presence of bacterial lysate as a
nonspecific competitor. Next, we purchased purified re-
combinant sCLU-His proteins that were expressed in
mouse cells, to perform surface plasmon resonance assay,
which indicated a very strong binding affinity between
sCLU and the active domain of MMP-9, with an affinity
constant (equilibrium dissociation constant KD) of 2.63
nmol/L (Figure 1B). Next, because there are various known
MMP-9 substrates, we tested whether CLUmight be a novel
enzymatic substrate of MMP-9; however, we found that CLU
is not a substrate of active MMP-9 (data not shown).
Because these results indicated in vitro interaction of
MMP-9 and CLU, we then asked whether the interaction
could occur in human epithelial cells. Because CLU pro-
teins are present mainly as sCLU, we first tested whether
anti-HA antibody, followed by Western blotting (WB) with anti-Myc antibody. In,
whole-cell lysate as input; IP, immunoprecipitated sample.
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environment. A conditioned medium from HCLE cell cul-
ture was subjected to IP assay with anti-MMP-9 antibody
(Figure 1C). Protein sample from the IP contained both
pro-MMP-9 and sCLU, suggesting their extracellular in-
teraction. Next, we tested their intracellular interaction
under confocal microscopy of HCLE cells immunostained
with MMP-9-specific and CLU-specific antibodies (Figure
1D). Both proteins were distributed throughout cyto-
plasm, more in the perinuclear region, and the composite
image indicated that they were mostly colocalized.
We then asked whether there is a physical interaction
between the two proteins, and what kinds of CLU iso-
forms bind to pro-MMP-9 inside cells. Three different CLU
isoforms are present in the cytoplasm: unprocessed non-
glycosylated (50 kDa) and glycosylated single peptide
(psCLU, 60 kDa), as well as processed glycosylated
dimeric sCLU ( 80 kDa).13 We first attempted IP assay
using the HCLE whole-cell extract, but could not detect
any MMP-9 or CLU protein bands; perhaps the amounts
of these proteins inside the cells were too low to support
IP assay. In an alternative approach, HEK293 cells were
transfected with MMP-9-HA and CLU-Myc expressing
vectors, individually and in combination (Figure 1E). The
results showed two protein bands, corresponding to the
sizes of psCLU (60 kDa) and sCLU -subunit (40 kDa),
only in the IP lane of cotransfection. We also noticed a band
(50 kDa) in the same lane that was slightly stronger, com-
pared with the other two IP lanes, which may correspond to
a nonglycosylated single peptide of CLU. Unfortunately,
because this band coincides with the position of the IgG
heavy chain of IP antibodies nonspecifically cross-reacting
with Western blotting antibodies, we could not conclusively
identify the band. The combined results suggested that
sCLU and psCLU interact with pro-MMP-9 and active
MMP-9 both inside and outside the cells.
CLU Binds to Pro-MMP-9 with a Higher Affinity
than Processed MMP-9
Because the results so far indicated that sCLU binds to both
pro- and active MMP-9, we next compared the relative
binding affinities for these MMP-9 isoforms. To do this, we
performed an enrichment assay by incubating recombinant
sCLU-His with a mixture of pro-MMP-9 and active MMP-9,
followed by a His-tag pull-down step (Figure 2A). The pro-
MMP-9 was prepared by treating it with APMA. The MMP-9
isoforms present in the input mixture and the final precipi-
tate were visualized with gelatin zymography. In the input
mixture, the processed MMP-9 was more abundant than
pro-MMP-9. In contrast, there was greater enrichment of
pro-MMP-9 in the anti-His beads sample, and comparison
of relative densities of these bands using ImageJ analysis
indicated approximately 10 times greater sCLU enrichment
of pro-MMP-9 than of processed MMP-9.
Because we found that MMP-2 also binds to sCLU under
the same binding assay conditions (data not shown), we
next performed a similar experiment with MMP-2 isoforms
included in the reaction (Figure 2B). The results indicated,A
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Figure 1. CLU binds to MMP-9 in vitro and in vivo. A: GST pull-down assay was
performed using MMP-9-GST and CLU71-HA in the presence () or absence ()
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anti-HA antibody. B: Surface plasmon resonance assay was performed to measure
specific binding of 100, 25, and 12.5 nM sCLU to immobilized catalytic domain of
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magnification,400. E:Whole-cell extracts from the transfected HEK293 cells with
the plasmid vectors expressing MMP-9-HA and CLU-Myc were subjected to IP withnotably, that sCLU showed no preference toward pro-
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MMP-9, indicating that pro-MMP-9 has a unique high affinity
for sCLU. To better understand the molecular interaction
between pro-MMP-9 and sCLU (Figure 2C), we prepared a
complex of pro-MMP-9 and sCLU-His, in which sCLU-His
was coupled to agarose beads, and then treated the com-
plex with and without APMA, followed by separating by
centrifugation into beads and supernatant fractions. We
reasoned that if sCLU binds preferentially to the propeptide
domain, the processed MMP-9 would be released from
the beads and partitioned into the fraction S; otherwise, the
processed enzyme would be in the bead fraction. Gelatin
zymography of the supernatant and bead samples indi-
cated that the majority of the processed MMP-9 was de-
tected in the supernatant fraction of APMA-treated reaction,
suggesting the direct involvement of the propeptide domain
in their interaction, by directly binding to sCLU or mediating/
stabilizing.
CLU Prevents Stress-Induced MMP-9
Aggregation
Extracellular proteins are vulnerable to stress-induced
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Figure 2. sCLU has a higher affinity for pro-MMP-9, mediated by the N-ter-
minal propeptide domain. A: A mixture of pro-MMP-9 and APMA-processed
MMP-9 (proc-MMP-9) was incubated with His-tagged sCLU, followed by
pulling down with agarose beads coupled with His-antibody (anti-His-beads)
or beads alone (Beads), and visualized with gelatin zymography. Serial
dilutions of each sample were loaded to facilitate comparison among sam-
ples. B: The same experiment was performed as for A, but also including
pro-MMP-2. C: ProMMP-9 that was prebound to CLU coupled to agarose
beads was incubated in the presence () or absence () of APMA, before
separation of bead (B lanes) and supernatant (S lanes) fractions, which were
then resolved with zymography.structural alteration, leading to their aggregation, whichcan have harmful effects in vivo. We investigated whether
MMP-9 aggregation could be caused by hydrophobic
stress, generated by the treatment with nonionic deter-
gents of different detergent properties (ie, Brij-35, NP-40,
and n-octyl glucopyranoside), and whether aggregation
could be prevented by adding sCLU in the reaction. We
incubated pro-MMP-9 and pro-MMP-2 in the enzyme re-
action buffer containing each of these detergents at
0.04% in the presence of sCLU or PBS as control (Figure
3). The soluble and insoluble fractions were separated by
centrifugation and visualized with gelatin zymography.
Brij-35 and NP-40 had little effect on the solubility of
pro-MMP-2 and pro-MMP-9. In contrast, the solubility of
these two MMPs was significantly reduced to 40% in
the presence of n-octyl glucopyranoside, and these re-
ductions were prevented by sCLU cotreatment.
CLU Inhibits the Enzymatic Activity and Function
of MMP-9
To assess the functional aspects of the interaction between
MMP-9 and CLU, we performed in vitro inhibition assays for
various MMPs, including MMP-9 (Figure 4A). We performed
FRET assay using catalytic domains of MMP-3 (stromelysin 1)
andMMP-9 (gelatinase B) andAPMA-processedMMP-2 (gel-
atinase A) andMMP-7 (matrilysin 1), as well as fluorescence-
quenched peptide substrates. MMP-7 naturally lacks the
C-terminal hemopexin domain. SB-3CT is a potent chemical
inhibitor selective to MMP-9 and MMP-2, with inhibition con-
stants in the submicromolar range.40 sCLU strongly inhib-
ited the activity of MMP-9 catalytic domain by 79% in a
dose-dependent manner; it also inhibited the activity of
APMA-processed MMP-9 dose-dependently and to a sim-
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Figure 3. sCLU prevents detergent stress-induced MMP-2 and MMP-9 aggre-
gation. Pro-MMP-2 or pro-MMP-9 was incubated in the buffer containing
0.04% of Brij-35, NP-40, or n-octyl glucopyranoside (OG) in the presence ()
or absence () of sCLU, and then the soluble (S) and insoluble (P) fractions,
obtained by centrifugation, were resolved by gelatin zymography. Relative
soluble fraction was calculated by ImageJ analysis.
Interaction of Clusterin and MMP-9 2035
AJP May 2012, Vol. 180, No. 5ilar extent (data not shown). In the present set of experi-
ments, MMP-2 was also inhibited by 65%, MMP-3 by 93%,
and MMP-7 by 17%, indicating that CLU can inhibit in vitro
enzymatic activity not only of MMP-9 but also of various
other MMPs.
We then examined the significance of the sCLU-mediated
inhibition ofMMP-9 activity at the cellular level. Recently, sCLU
wasshown toprotect TJ structure fromdegradationcausedby
oxidative stress to endothelial cell culture.41 Active MMP-9 is
known todegrade the TJ structure formed in the apical surface
of epithelia.9 Therefore, by immunofluorescent staining of
ZO-1, a TJ component protein, we tested whether CLU could
affect the MMP-9-mediated destruction of TJ that formed in a
confluent culture of human breast epithelial cancer cells (Fig-
ure 4B). Untreated control demonstrated typical continuous
chicken-wire pattern of TJ. In contrast, the treatment of active
MMP-9 caused many breakages in the TJ continuum and
significantly reduced ZO-1 density by 51%, compared with
control. However, cotreatment with sCLU prevented MMP-9
mediated ZO-1 degradation. We also performed Western
blotting to confirm the above immunofluorescent staining
results, showing that ZO-1 protein was decreased with
MMP-9 treatment, which was abrogated by cotreatment
with sCLU (Figure 4C).
CLU Expression Is Down-Regulated by
Proinflammatory Factors Such As Cytokines
and Desiccating Stress
The inflammatory process involves increased activities of
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Figure 4. sCLU prevents activity and function of MMP-9.A: Enzymatic reactions
of MMP-9, MMP-2, MMP-3, and MMP-7 were performed in the presence of sCLU
or SB-3CT (SB). Relative fluorescence units (RFU) were obtained by setting PBS
as 100%. Each reaction was performed in triplicate. Error bars indicate SE. *P 
0.01; **P  0.0001 versus untreated control, Student’s t-test. n  3. B: Confocal
fluorescence image analysis was performed for ZO-1 protein after exposing
confluent MCF-7 cell culture to active MMP-9 alone (M) or in combination with
sCLU (MC). The relative densities of ZO-1 were quantified over untreated (U)
control, using Velocity software. *P  0.01. n  12. C: Western blotting with
protein extracts from the cells treated with MMP-9 and CLU was performed for
ZO-1 detection (-actin, control).various proinflammatory cytokines, as well as of MMP-9.42 We wanted to see how CLU expression is regulated
under the inflammatory conditions in which MMP-9 is
up-regulated. We first examined the transcriptional
change in MMP-9 and CLU in HCLE cells exposed to
IL-1, TGF-2, phorbol myristate acetate (PMA), or
TNF-, all of which are known to increase the production
of MMP-9 (Figure 5A). In all four cases, the exposure
increased MMP-9 expression and decreased CLU.
Furthermore, we observed an intriguing correlation, in
that the more MMP-9 was produced, the less CLU was
expressed.
Because up-regulated MMP-9 is actively involved in
inflammatory conditions such as DE,9 we wanted to see
how CLU and MMP-9 interact in an in vivo animal model.
C57BL/6J mice have been broadly used as a model
animal for human DE study. Desiccating stress is known
to induce DE.38,43 We housed mice in a warm, low-hu-
midity vivarium for 6 days, and we regularly injected
scopolamine hydrobromide to reduce tear production.
First, we asked where MMP-9 and CLU are distributed in
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Figure 5. CLU is down-regulated in the corneal epithelial cells on cytokines
and desiccating stress treatments. A: HCLE cells were treated by IL-1,
TGF-2, PMA, and TNF-. The expression of MMP-9 and of CLU was mea-
sured by RT-PCR, and fold induction was normalized using -actin transcrip-
tion. B: Immunolocalization of CLU (red) and MMP-9 (green) by fluorescence
immunostaining with anti-CLU and anti-MMP-9 antibodies was performed
using the frozen section of the eye from the untreated normal C67BL/6J mice.
One of four representative eyes is shown. Nuclei (DAPI, blue) are shown
only in composite images. C: DE was induced in mice by desiccating stress
for 6 days, and the tear volumes were measured in untreated and treated
mice. *P  0.01. n  10 eyes. Distributions of CLU and MMP-9 in untreated
(Unt) and DE-induced (DE) mouse eyes are shown. One of four represen-
tative eyes is shown. D: Quantitative RT-PCR and Western blotting were
performed to confirm the changes in CLU and MMP-9 expressions in the
ocular surface epithelium in untreated and DE mice. †P  0.01. n  8 eyes.
2036 Jeong et al
AJP May 2012, Vol. 180, No. 5the corneal tissue sections from healthy mice (Figure 5B).
MMP-9 is known to express minimally in the healthy oc-
ular surface, so that it is rarely detected biochemically in
the tear fluid,9 but the immunofluorescent staining
method allows its detection in the healthy cornea. In the
healthy cornea, both MMP-9 and CLU were detected only
in the anterior half of the corneal epithelium. Of note,
spatial distributions of both CLU and MMP-9 proteins
seem very similar, but CLU is distributed more anteriorly
and MMP-9 more posteriorly. Strong colocalization in the
ocular surface (Figure 5B) is consistent with our biochem-
ical and cell culture results. After DE induction in the mice
(Figure 5C), we first confirmed that the mice with DE had
reduced tear volume, compared with the untreated mice.
We next compared the expression and distribution of
CLU and MMP-9 in the cornea in both mice groups. In
acquiring the fluorescence images from these groups,
we captured and processed images with identical pho-
tomultiplier tube gain settings for accurate comparison
within pairs.38 In the ocular surface from untreated con-
trol mice, CLU was prominent; however, its expression
was markedly diminished after DE induction, whereas
MMP-9 was increased and predominant along the apical
layer of the epithelium. We also performed quantitative
RT-PCR and Western blotting, to evaluate expression
changes of CLU and MMP-9 at the transcriptional and
post-transcriptional levels after DE induction, and con-
firmed the conclusions from the florescence image anal-
ysis (Figure 5D). Increase in MMP-9 expression has been
reported previously for similar desiccating stress condi-
tions.38,39 Western blotting revealed various species of
CLU, reflecting post-translational CLU processing, such
as nonglycosylated nascent psCLU and intermediately
and fully glycosylated psCLU, as well as mature sCLU
molecules present in the ocular surface epithelium. West-
ern blotting further confirmed the reduction of the amount
of CLU proteins after DE induction.
Discussion
The expression and activation of MMP-9 is tightly con-
trolled under normal conditions, but its regulation is al-
tered in many inflammatory diseases. Dysregulated
MMP-9 activity is associated with the destruction of TJs,
a key constituent of epithelial barrier integrity.9,44 MMP-9
is also able to proteolytically activate latent precursors of
proinflammatory cytokines, such as interleukin-1 (IL-
1), transforming growth factor- (TGF-), and mem-
brane-bound tumor necrosis factor- (TNF-).45–47 Sev-
eral proteins have known regulatory functions involving
MMP-9. Tissue inhibitor of MMPs (TIMPs) interact with
and inhibit the active site of MMP-9, and the C-terminal
region of TIMP-1 is known to bind to the hemopexin
domain of both pro-MMP-9 and processed MMP-9.48,49
Extracellular matrix protein 1 (ECM1) also inhibits MMP-9
activity, through their interaction.50 DNA repair protein Ku
was shown to interact with the hemopexin domain of
MMP-9 at the cell surface and to be involved in cellular
invasion of collagen type IV matrices.51 Neutrophil gela-tinase-associated lipocalin (NGAL) was shown to com-
plex with MMP-9 and protect it from degradation.52
Our observation that both bacterially expressed single-
chain CLU peptide and psCLU bind to MMP-9 indicates
that post-translational modifications of CLU, such as gly-
cosylation and heterodimerization, may not be necessary
for the CLU-MMP-9 interaction. Our present findings dis-
tinguish sCLU from TIMPs, in that sCLU has a far higher
binding affinity (KD  2.63 nmol/L) for the catalytic do-
main of MMP-9 than do TIMP-1 and TIMP-2, which have
affinities of KD  24 and 58 nmol/L, respectively, for the
same domain; furthermore, sCLU prefers the N-terminal
propeptide domain, whereas TIMPs have higher affinities
for the C-terminal hemopexin domain over other domains
of MMP-9.53
CLU is constitutively present at most fluid-tissue inter-
faces, and was proposed to protect those epithelial bar-
rier from the surface-active components of the extracel-
lular environment almost two decades ago.54 The present
study demonstrates previously unrecognized unique in-
teractions of CLU and MMP-9 proteins, in that they
strongly interact with each other both inside and outside
cells, even before their processing and secretion. Inhibi-
tion of MMP-9 activity by sCLU results from the direct
interaction of CLU with the catalytic domain of MMP-9.
We also observed that sCLU inhibits the enzymatic ac-
tivities of MMP-3 and MMP-7, which can activate pro-
MMP-9.55,56 MMP-3 was found exclusively in the eyes of
patients with DE, and MMP-3 activity was implicated in
the pro-MMP-9 activation in the tear fluid.56 Our results
thus suggest that sCLU can abrogate MMP-9 functions,
directly and indirectly, by inhibiting the activities of both
active MMP-9 and pro-MMP-9 activating enzymes.
It is also noteworthy that sCLU has far higher affinity for
pro-MMP-9, but not pro-MMP-2, than the processed
MMP-9, which is mediated by the N-terminal propeptide
domain, implying a functional role of CLU in MMP-9 reg-
ulation. In this sense, one possibility is that sCLU bound
to pro-MMP-9 via the propeptide domain may interfere
with the activating process of pro-MMP-9 by, for exam-
ple, sterically hindering the access of the cleavage site to
activating enzymes (eg, plasmin, MMP-3, and MMP-7).
Although CLU is secreted through the endoplasmic
reticulum-Golgi body pathway, it is also present as ps-
CLU in cytosol compartments.24,57 It has been sug-
gested that the role of CLU is determined by its final
location.57 Increased CLU expression was reported to
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Figure 6. A model for the regulatory roles of CLU in MMP-9 metabolism
inside and outside cells. psCLU and sCLU proteins interact with pro-MMP-9
and activated MMP-9 at multiple stages of MMP-9 metabolism inside and
outside cells. CLU proteins may inhibit transcription, secretion, activation
(processing), and/or activity of MMP-9, while also promoting the clearance of
MMP-9 from the extracellular compartments.
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smooth muscle cells.28 psCLU prevents I-B degrada-
tion, leading to inhibition of the NF-B nuclear localiza-
tion.26 psCLU binds to Bax, a proapoptotic protein, and
serves as its cytosol retention factor, functioning as a
antiapoptotic component in cells under stress.24,58 It is
also shown that CLU can retrotranslocate into cytosol
under certain cellular stress conditions.57 MMP-9 is found
in intracellular, pericellular, and extracellular compart-
ments and even in the nucleus.59 Given that CLU is a
stress-induced, cytoprotective protein,20 it would be
worthwhile to determine whether, under certain condi-
tions, increased CLU expression can affect some as-
pects of MMP-9 metabolism (eg, subcellular localization
and secretion).
Secreted proteins are vulnerable to stress-induced de-
naturation and aggregation, which may be toxic to the
cells and are to be eventually removed from their target
sites.60 Clearance of extracellular MMPs by cellular inter-
nalization has been suggested and observed for MMP-2,
MMP-9, and MMP-13. MMP-2 forms a complex with
thrombospondin-2 (TSP-2),61 and MMP-9 does so with
TIMP-1 in vitro,18,62 to be internalized into the cells by
recognizing a common cell surface receptor, LRP-2/
megalin/gp330, on the cell surface. MMP-13 also in-
volves a specific MMP-13 receptor and LRP receptor for
internalization.63 In this sense, it is noteworthy that CLU is
also known to be internalized via the LRP-2 receptor.19,64
Our present observation of the promotion of MMP-9 sol-
ubility by sCLU under detergent stress conditions leads
us to speculate that CLU-MMP complex formation may
contribute to MMP-9 solubility, which might otherwise be
compromised by denaturing or aggregating stresses,
and it may facilitate cellular MMP-9 internalization via
LRP-2 receptors in a more regulated way, ending up with
its degradation inside the cells. sCLU may work as an
extracellular vehicle to deliver pro-MMP-9 to LRP-2, play-
ing its stress-associated cytoprotective roles. In support
of this idea, sCLU was observed to promote clearance of
cellular debris via the cell surface receptor LRP-2.19,60
LRP-2 is typically found on the apical surface of epithe-
lium in several organs.65,66 Thus, we envision that CLU
may promote the internalization of activated and pro-
MMP-9, leading to their clearance and degradation in-
side the epithelial cells.
CLU has anti-inflammatory functions in vivo. Low levels
of CLU are correlated with the occurrence or severity of
various inflammations in patients and in mouse models.
Some inflammatory diseases (eg, rheumatoid arthritis
and systemic erythematosus lupus) that present with DE
as a pathological feature become more severe, in a
mouse model, when CLU protein is deficient.67,68 In-
creased MMP-9 activity was associated with keratiniza-
tion of human keratinocytes.69,70 CLU expression is
markedly decreased in pathological, keratinized corneal
epithelium from patients.71 In a mouse injury model using
C57BL/6J mice, CLU was recently found to play a critical
role in promoting pancreas regeneration after injury and
in vitro -cell regeneration.33 In human DE disease, ele-
vated MMP-9 activity has been recognized as a main
cause for derangement of corneal epithelial barrier func-tion in DE.9 In a mouse model of DE disease, MMP-9
expression was significantly enhanced on DE induc-
tion.38 Our data indicate that CLU is localized at the
superficial cell layer of the untreated healthy mouse cor-
neal epithelium, where it is being bound to MMP-9; CLU
thus appears to be confining MMP-9 molecules inside the
mouse corneal epithelium. MMP-9 is up-regulated on DE
induction and CLU expression is dramatically dimin-
ished, suggesting that down-regulation of CLU may be
implicated in the onset of DE disease. CLU was recently
reported to induce in vitro MMP-9 expression in mono-
cytes/macrophages.72 Given that the role of CLU ap-
pears to vary depending on cell types, stimulus, and/or
the tissue microenvironment,72 it would be worthwhile to
investigate the in vivo function of CLU in the context of
ocular surface homeostasis and DE, which also involves
various immune cells as well as epithelial cells.
The complexity of inflammatory pathology in the ocular
surface with DE presents a challenging problem, one with
few therapeutic options. A key to successful treatment
may be the identification and targeting of a critical, func-
tional player in the inflammatory cycle constituted by
cytokines, chemokines, mediators, and MMPs, all of
which are produced by ocular surface epithelial cells and
recruited immune cells.42 From this point of view, MMP-9
could be a prime therapeutic target in that, in addition to
its destructive enzymatic activity, it activates latent pro-
inflammatory cytokines, which in turn up-regulate MMP-9
production and thereby critically contribute to sustaining
of such morbid cycles in DE disease. Further elucidation
of the roles of CLU proteins in the ocular surface using
wild-type and CLU-deficient mice is warranted, and such
studies may lead to prophylactic or therapeutic benefit in
inflammatory diseases.
In summary, our results suggest that CLU modulates
MMP-9 functions at multiple stages of its metabolism,
including secretion, activation, enzymatic activity, and
clearance (Figure 6), providing novel insight into a mech-
anism by which a number of intracellular and extracellular
CLU-interacting proteins may be similarly regulated by CLU
in the body. We also propose that the constitutive CLU
expression in epithelia exposed to continuous external
stress may serve as a previously unrecognized homeo-
stasis mechanism, which works both inside and outside
of the epithelial cells.
Acknowledgment
We thank Dr. Ilene Gipson (Harvard Medical School) for
kindly providing the HCLE line.
References
1. Pflugfelder SC: Prevalence, burden, and pharmacoeconomics of dry
eye disease. Am J Manag Care 2008, 14:S102–S106
2. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of
metalloproteinases: structure, function, and biochemistry. Circ Res
2003, 92:827–839
3. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T: Regulation
of matrix metalloproteinases: an overview. Mol Cell Biochem 2003,
253:269–285
2038 Jeong et al
AJP May 2012, Vol. 180, No. 54. Gordon GM, Austin JS, Sklar AL, Feuer WJ, Lagier AJ, Fini ME:
Comprehensive gene expression profiling and functional analysis of
matrix metalloproteinases and TIMPs, and identification of ADAM-10
gene expression, in a corneal model of epithelial resurfacing. J Cell
Physiol 2011, 226:1461–1470
5. Van Wart HE, Birkedal-Hansen H: The cysteine switch: a principle of
regulation of metalloproteinase activity with potential applicability to
the entire matrix metalloproteinase gene family. Proc Natl Acad Sci
USA 1990, 87:5578–5582
6. Mohan R, Chintala SK, Jung JC, Villar WV, McCabe F, Russo LA, Lee
Y, McCarthy BE, Wollenberg KR, Jester JV, Wang M, Welgus HG,
Shipley JM, Senior RM, Fini ME: Matrix metalloproteinase gelatinase B
(MMP-9) coordinates and effects epithelial regeneration. J Biol Chem
2002, 277:2065–2072
7. Fini ME, Parks WC, Rinehart WB, Girard MT, Matsubara M, Cook JR,
West-Mays JA, Sadow PM, Burgeson RE, Jeffrey JJ, Raizman MB,
Krueger RR, Zieske JD: Role of matrix metalloproteinases in failure to
re-epithelialize after corneal injury. Am J Pathol 1996, 149:1287–1302
8. Matsubara M, Zieske JD, Fini ME: Mechanism of basement mem-
brane dissolution preceding corneal ulceration. Invest Ophthalmol Vis
Sci 1991, 32:3221–3237
9. Pflugfelder SC, Farley W, Luo L, Chen LZ, de Paiva CS, Olmos LC, Li
DQ, Fini ME: Matrix metalloproteinase-9 knockout confers resistance
to corneal epithelial barrier disruption in experimental dry eye. Am J
Pathol 2005, 166:61–71
10. Chotikavanich S, de Paiva CS, Li DQ, Chen JJ, Bian F, Farley WJ,
Pflugfelder SC: Production and activity of matrix metalloproteinase-9
on the ocular surface increase in dysfunctional tear syndrome. Invest
Ophthalmol Vis Sci 2009, 50:3203–3209
11. Vermeer PD, Denker J, Estin M, Moninger TO, Keshavjee S, Karp P,
Kline JN, Zabner J: MMP9 modulates tight junction integrity and cell
viability in human airway epithelia. Am J Physiol Lung Cell Mol Physiol
2009, 296:L751–L762
12. Jones SE, Jomary C: Clusterin. Int J Biochem Cell Biol 2002, 34:427–
431
13. Trougakos IP, Djeu JY, Gonos ES, Boothman DA: Advances and
challenges in basic and translational research on clusterin. Cancer
Res 2009, 69:403–406
14. Falgarone G, Chiocchia G: Chapter 8: clusterin: a multifacet protein at
the crossroad of inflammation and autoimmunity. Adv Cancer Res
2009, 104:139–170
15. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA: Synthesis and
functional analyses of nuclear clusterin, a cell death protein. J Biol
Chem 2003, 278:11590–11600
16. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G,
McCluskey RT, Frangione B, Ghiso J: Glycoprotein 330/megalin:
probable role in receptor-mediated transport of apolipoprotein J
alone and in a complex with Alzheimer disease amyloid beta at the
blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad
Sci USA 1996, 93:4229–4234
17. Wyatt AR, Yerbury JJ, Wilson MR: Structural characterization of clus-
terin-chaperone client protein complexes. J Biol Chem 2009, 284:
21920–21927
18. Hahn-Dantona E, Ruiz JF, Bornstein P, Strickland DK: The low density
lipoprotein receptor-related protein modulates levels of matrix metal-
loproteinase 9 (MMP-9) by mediating its cellular catabolism. J Biol
Chem 2001, 276:15498–15503
19. Kounnas MZ, Loukinova EB, Stefansson S, Harmony JA, Brewer BH,
Strickland DK, Argraves WS: Identification of glycoprotein 330 as an
endocytic receptor for apolipoprotein J/clusterin [Erratum appeared
in J Biol Chem 1995, 270:23234]. J Biol Chem 1995, 270:13070–
13075
20. Trougakos IP, Gonos ES: Chapter 9: oxidative stress in malignant
progression: the role of clusterin, a sensitive cellular biosensor of free
radicals. Adv Cancer Res 2009, 104:171–210
21. McDonald JF, Nelsestuen GL: Potent inhibition of terminal comple-
ment assembly by clusterin: characterization of its impact on C9
polymerization. Biochemistry 1997, 36:7464–7473
22. Murphy BF, Davies DJ, Morrow W, d’Apice AJ: Localization of termi-
nal complement components S-protein and SP-40,40 in renal biop-
sies. Pathology 1989, 21:275–278
23. Choi NH, Mazda T, Tomita M: A serum protein SP40,40 modulates the
formation of membrane attack complex of complement on erythro-
cytes. Mol Immunol 1989, 26:835–84024. Trougakos IP, Lourda M, Antonelou MH, Kletsas D, Gorgoulis VG,
Papassideri IS, Zou Y, Margaritis LH, Boothman DA, Gonos ES:
Intracellular clusterin inhibits mitochondrial apoptosis by suppressing
p53-activating stress signals and stabilizing the cytosolic Ku70-Bax
protein complex. Clin Cancer Res 2009, 15:48–59
25. Sensibar JA, Sutkowski DM, Raffo A, Buttyan R, Griswold MD, Syl-
vester SR, Kozlowski JM, Lee C: Prevention of cell death induced by
tumor necrosis factor alpha in LNCaP cells by overexpression of
sulfated glycoprotein-2 (clusterin). Cancer Res 1995, 55:2431–2437
26. Santilli G, Aronow BJ, Sala A: Essential requirement of apolipoprotein
J (clusterin) signaling for IkappaB expression and regulation of NF-
kappaB activity. J Biol Chem 2003, 278:38214–38219
27. Devauchelle V, Essabbani A, De Pinieux G, Germain S, Tourneur L,
Mistou S, Margottin-Goguet F, Anract P, Migaud H, Le Nen D, Le-
querre T, Saraux A, Dougados M, Breban M, Fournier C, Chiocchia G:
Characterization and functional consequences of underexpression of
clusterin in rheumatoid arthritis. J Immunol 2006, 177:6471–6479
28. Kim HJ, Yoo EK, Kim JY, Choi YK, Lee HJ, Kim JK, Jeoung NH, Lee
KU, Park IS, Min BH, Park KG, Lee CH, Aronow BJ, Sata M, Lee IK:
Protective role of clusterin/apolipoprotein J against neointimal hyper-
plasia via antiproliferative effect on vascular smooth muscle cells and
cytoprotective effect on endothelial cells. Arterioscler Thromb Vasc
Biol 2009, 29:1558–1564
29. McLaughlin L, Zhu G, Mistry M, Ley-Ebert C, Stuart WD, Florio CJ,
Groen PA, Witt SA, Kimball TR, Witte DP, Harmony JA, Aronow BJ:
Apolipoprotein J/clusterin limits the severity of murine autoimmune
myocarditis. J Clin Invest 2000, 106:1105–1113
30. Savkovic´ V, Gantzer H, Reiser U, Selig L, Gaiser S, Sack U, Klöppel
G, Mössner J, Keim V, Horn F, Bödeker H: Clusterin is protective in
pancreatitis through anti-apoptotic and anti-inflammatory properties.
Biochem Biophys Res Commun 2007, 356:431–437
31. Rosenberg ME, Girton R, Finkel D, Chmielewski D, Barrie A 3rd, Witte
DP, Zhu G, Bissler JJ, Harmony JA, Aronow BJ: Apolipoprotein
J/clusterin prevents a progressive glomerulopathy of aging. Mol Cell
Biol 2002, 22:1893–1902
32. Han BH, DeMattos RB, Dugan LL, Kim-Han JS, Brendza RP, Fryer JD,
Kierson M, Cirrito J, Quick K, Harmony JA, Aronow BJ, Holtzman DM:
Clusterin contributes to caspase-3-independent brain injury following
neonatal hypoxia-ischemia. Nat Med 2001, 7:338–343
33. Lee S, Hong SW, Min BH, Shim YJ, Lee KU, Lee IK, Bendayan M,
Aronow BJ, Park IS: Essential role of clusterin in pancreas regener-
ation. Dev Dyn 2011, 240:605–615
34. Argueso P, Tisdale A, Spurr-Michaud S, Sumiyoshi M, Gipson IK:
Mucin characteristics of human corneal-limbal epithelial cells that
exclude the rose bengal anionic dye. Invest Ophthalmol Vis Sci 2006,
47:113–119
35. Gordon GM, Ledee DR, Feuer WJ, Fini ME: Cytokines and signaling
pathways regulating matrix metalloproteinase-9 (MMP-9) expression
in corneal epithelial cells. J Cell Physiol 2009, 221:402–411
36. Murphy G, Crabbe T: Gelatinases A and B. Methods Enzymol 1995,
248:470–484
37. Gipson IK, Spurr-Michaud S, Argueso P, Tisdale A, Ng TF, Russo CL:
Mucin gene expression in immortalized human corneal-limbal and
conjunctival epithelial cell lines. Invest Ophthalmol Vis Sci 2003,
44:2496–2506
38. Corrales RM, Stern ME, De Paiva CS, Welch J, Li DQ, Pflugfelder SC:
Desiccating stress stimulates expression of matrix metalloprotei-
nases by the corneal epithelium. Invest Ophthalmol Vis Sci 2006,
47:3293–3302
39. Luo L, Li DQ, Doshi A, Farley W, Corrales RM, Pflugfelder SC: Exper-
imental dry eye stimulates production of inflammatory cytokines and
MMP-9 and activates MAPK signaling pathways on the ocular sur-
face. Invest Ophthalmol Vis Sci 2004, 45:4293–4301
40. Kleifeld O, Kotra LP, Gervasi DC, Brown S, Bernardo MM, Fridman R,
Mobashery S, Sagi I: X-ray absorption studies of human matrix met-
alloproteinase-2 (MMP-2) bound to a highly selective mechanism-
based inhibitor. Comparison with the latent and active forms of the
enzyme. J Biol Chem 2001, 276:17125–17131
41. Kim JH, Yu YS, Min BH, Kim KW: Protective effect of clusterin on
blood-retinal barrier breakdown in diabetic retinopathy. Invest Oph-
thalmol Vis Sci 2010, 51:1659–166542. Pflugfelder SC, de Paiva CS, Li DQ, Stern ME: Epithelial-immune cell
interaction in dry eye. Cornea 2008, 27 Suppl 1:S9–S11
Interaction of Clusterin and MMP-9 2039
AJP May 2012, Vol. 180, No. 543. Dursun D, Wang M, Monroy D, Li DQ, Lokeshwar BL, Stern ME,
Pflugfelder SC: A mouse model of keratoconjunctivitis sicca. Invest
Ophthalmol Vis Sci 2002, 43:632–638
44. Yi X, Wang Y, Yu FS: Corneal epithelial tight junctions and their
response to lipopolysaccharide challenge. Invest Ophthalmol Vis Sci
2000, 41:4093–4100
45. Kiaei M, Kipiani K, Calingasan NY, Wille E, Chen J, Heissig B, Rafii S,
Lorenzl S, Beal MF: Matrix metalloproteinase-9 regulates TNF-alpha
and FasL expression in neuronal, glial cells and its absence extends
life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp
Neurol 2007, 205:74–81
46. Schönbeck U, Mach F, Libby P: Generation of biologically active IL-1
beta by matrix metalloproteinases: a novel caspase-1-independent
pathway of IL-1 beta processing. J Immunol 1998, 161:3340–3346
47. Yu Q, Stamenkovic I: Cell surface-localized matrix metalloprotei-
nase-9 proteolytically activates TGF-beta and promotes tumor inva-
sion and angiogenesis. Genes Dev 2000, 14:163–176
48. Maskos K, Bode W: Structural basis of matrix metalloproteinases
and tissue inhibitors of metalloproteinases. Mol Biotechnol 2003,
25:241–266
49. O’Connell JP, Willenbrock F, Docherty AJ, Eaton D, Murphy G: Anal-
ysis of the role of the COOH-terminal domain in the activation, pro-
teolytic activity, and tissue inhibitor of metalloproteinase interactions
of gelatinase B. J Biol Chem 1994, 269:14967–14973
50. Fujimoto N, Terlizzi J, Aho S, Brittingham R, Fertala A, Oyama N,
McGrath JA, Uitto J: Extracellular matrix protein 1 inhibits the activity
of matrix metalloproteinase 9 through high-affinity protein/protein in-
teractions. Exp Dermatol 2006, 15:300–307
51. Monferran S, Paupert J, Dauvillier S, Salles B, Muller C: The mem-
brane form of the DNA repair protein Ku interacts at the cell surface
with metalloproteinase 9. EMBO J 2004, 23:3758–3768
52. Yan L, Borregaard N, Kjeldsen L, Moses MA: The high molecular
weight urinary matrix metalloproteinase (MMP) activity is a complex of
gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin
(NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001,
276:37258–37265
53. Olson MW, Gervasi DC, Mobashery S, Fridman R: Kinetic analysis of
the binding of human matrix metalloproteinase-2 and -9 to tissue
inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem 1997,
272:29975–29983
54. Aronow BJ, Lund SD, Brown TL, Harmony JA, Witte DP: Apolipopro-
tein J expression at fluid-tissue interfaces: potential role in barrier
cytoprotection. Proc Natl Acad Sci USA 1993, 90:725–729
55. Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N, Okada
Y: Matrix metalloproteinase 7 (matrilysin) from human rectal carci-
noma cells. Activation of the precursor, interaction with other matrix
metalloproteinases and enzymic properties. J Biol Chem 1995, 270:
6691–6697
56. Sobrin L, Liu Z, Monroy DC, Solomon A, Selzer MG, Lokeshwar BL,
Pflugfelder SC: Regulation of MMP-9 activity in human tear fluid and
corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci
2000, 41:1703–1709
57. Nizard P, Tetley S, Le Drean Y, Watrin T, Le Goff P, Wilson MR, Michel
D: Stress-induced retrotranslocation of clusterin/ApoJ into the cyto-
sol. Traffic 2007, 8:554–56558. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY: Clus-
terin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol
2005, 7:909–915
59. Sbai O, Ould-Yahoui A, Ferhat L, Gueye Y, Bernard A, Charrat E,
Mehanna A, Risso JJ, Chauvin JP, Fenouillet E, Rivera S, Khrest-
chatisky M: Differential vesicular distribution and trafficking of MMP-2,
MMP-9, and their inhibitors in astrocytes. Glia 2009, 58:344–366
60. Wyatt AR, Yerbury JJ, Berghofer P, Greguric I, Katsifis A, Dobson CM,
Wilson MR: Clusterin facilitates in vivo clearance of extracellular
misfolded proteins. Cell Mol Life Sci 2011, 68:3919–3931
61. Yang Z, Strickland DK, Bornstein P: Extracellular matrix metallopro-
teinase 2 levels are regulated by the low density lipoprotein-related
scavenger receptor and thrombospondin 2. J Biol Chem 2001, 276:
8403–8408
62. Van den Steen PE, Van Aelst I, Hvidberg V, Piccard H, Fiten P,
Jacobsen C, Moestrup SK, Fry S, Royle L, Wormald MR, Wallis R,
Rudd PM, Dwek RA, Opdenakker G: The hemopexin and O-glycosy-
lated domains tune gelatinase B/MMP-9 bioavailability via inhibition
and binding to cargo receptors. J Biol Chem 2006, 281:18626–18637
63. Barmina OY, Walling HW, Fiacco GJ, Freije JM, Lopez-Otin C, Jeffrey
JJ, Partridge NC: Collagenase-3 binds to a specific receptor and
requires the low density lipoprotein receptor-related protein for inter-
nalization. J Biol Chem 1999, 274:30087–30093
64. Ammar H, Closset JL: Clusterin activates survival through the phos-
phatidylinositol 3-kinase/Akt pathway. J Biol Chem 2008, 283:12851–
12861
65. Zheng G, Bachinsky DR, Stamenkovic I, Strickland DK, Brown D,
Andres G, McCluskey RT: Organ distribution in rats of two members
of the low-density lipoprotein receptor gene family, gp330 and LRP/
alpha 2MR, and the receptor-associated protein (RAP). J Histochem
Cytochem 1994, 42:531–542
66. Kounnas MZ, Haudenschild CC, Strickland DK, Argraves WS: Immu-
nological localization of glycoprotein 330, low density lipoprotein
receptor related protein and 39 kDa receptor associated protein in
embryonic mouse tissues. In Vivo 1994, 8:343–351
67. Newkirk MM, Apostolakos P, Neville C, Fortin PR: Systemic lupus
erythematosus, a disease associated with low levels of clusterin/
apoJ, an antiinflammatory protein. J Rheumatol 1999, 26:597–603
68. Høgåsen K, Mollnes TE, Harboe M, Götze O, Hammer HB, Opper-
mann M: Terminal complement pathway activation and low lysis
inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol 1995,
22:24–28
69. Kobayashi T, Kishimoto J, Ge Y, Jin W, Hudson DL, Ouahes N,
Ehama R, Shinkai H, Burgeson RE: A novel mechanism of matrix
metalloproteinase-9 gene expression implies a role for keratinization.
EMBO Rep 2001, 2:604–608
70. Pi J, Diwan BA, Sun Y, Liu J, Qu W, He Y, Styblo M, Waalkes MP:
Arsenic-induced malignant transformation of human keratinocytes:
involvement of Nrf2. Free Radic Biol Med 2008, 45:651–658
71. Nakamura T, Nishida K, Dota A, Kinoshita S: Changes in conjunctival
clusterin expression in severe ocular surface disease. Invest Oph-
thalmol Vis Sci 2002, 43:1702–1707
72. Shim YJ, Kang BH, Jeon HS, Park IS, Lee KU, Lee IK, Park GH, Lee
KM, Schedin P, Min BH: Clusterin induces matrix metalloproteinase-9
expression via ERK1/2 and PI3K/Akt/NF-kappaB pathways in mono-
cytes/macrophages. J Leukoc Biol 2011, 90:761–769
